Erken Kanserde Metabolik Yeniden Programlama: Değişmiş Şeker ve Tümör Oluşumundaki Rolü

Öz

Metabolik yeniden programlama, kanserin bir belirteci olup, kanserojenez ve kanser gelişiminin ilk aşamalarında önemli bir rol oynar. Bu fenomen, özellikle tümör büyümesi ve yayılması için gerekli enerji ve yapı taşlarını sağlayan şekerlerin kullanımında olmak üzere, hücresel metabolizmadaki değişiklikleri içerir. Bu inceleme, erken kanserle ilişkili metabolik yeniden programlamaya ve bunun şeker metabolizması üzerindeki etkisine odaklanmaktadır. Kanser hücreleri, Adenozin Trifosfat üretimi ve biyokütle sentezini hızlandıran, genellikle Warburg etkisi olarak bilinen, artmış glukoz alımı ve kullanımını sergiler. Ayrıca, kanser hücreleri artan glikoliz akışı gösterir, glukoz metabolitlerini hücre büyümesini destekleyen anabolik yollara yönlendirir. Onkogenik sinyal yolları, anahtar düzenleyicilerin aktivasyonu ve p53 geni gibi tümör baskılayıcı genlerdeki değişiklikler dahil olmak üzere, şeker metabolizmasındaki bu değişiklikleri yönlendirir. Kanser hücrelerinde şeker metabolizmasının yenilenmesi, tümörün hayatta kalmasını ve ilerlemesini kolaylaştırarak seçici bir avantaj sağlar. Ayrıca, erken evre kanserdeki metabolik değişiklikler, biyosentez, redoks dengesi ve post-translasyonel modifikasyonlar için ara maddelerin oluşumunu teşvik ederek tümör oluşumuna daha fazla katkıda bulunur. Erken kanserde metabolik yeniden programlamanın karmaşıklıklarını anlamak, metabolik zayıflıkları hedefleyen başarılı tedavi yöntemleri geliştirmek için esastır. Kanser hücrelerinin değişmiş şeker metabolizmasına olan bağımlılığını bozmayı amaçlayan terapötik müdahaleler, tümör büyümesini durdurma ve hasta sonuçlarını iyileştirme konusunda büyük bir umut taşımaktadır.

Anahtar Kelimeler

• Glikoliz
• Kanser hucreleri
• PPP
• GLUTlar
• NADPH

Metabolic Reprogramming in Early Cancer: Altered Sugar and its Role in Tumorigenesis

Öz

Metabolic reprogramming is a hallmark of cancer, playing an essential role in carcinogenesis and the initial steps of cancer development. This phenomenon involves alterations in cellular metabolism, particularly in using sugars, which provide the essential energy and building blocks for tumour growth and propagation. This review focuses on the metabolic reprogramming associated with early cancer and its impact on sugar metabolism. Cancer cells exhibit enhanced glucose uptake and utilisation, commonly known as the Warburg effect, which allows for rapid Adenosine Triphosphate production and biomass synthesis. Additionally, cancer cells demonstrate increased glycolytic flux, diverting glucose metabolites towards anabolic pathways that support cell growth. Oncogenic signalling pathways, including activation of key regulators and alterations in tumour suppressor genes such as the p53 gene, drive these alterations in sugar metabolism. Renewing sugar metabolism in cancer cells provides a selective advantage, facilitating tumour survival and progression. Moreover, metabolic alterations in early cancer promote the generation of intermediates for biosynthesis, redox balance, and post-translational modifications, further contributing to tumorigenesis. Comprehending the complexities of metabolic reprogramming in early cancer is essential for formulating successful treatment methods that target metabolic vulnerabilities. Therapeutic interventions aimed at disrupting cancer cells' addiction to altered sugar metabolism hold great promise in halting tumour growth and improving patient outcomes.

Anahtar Kelimeler

• Glycolysis
• Cancer Cells
• PPP
• GLUTs
• NADPH

Kaynakça

1. Upadhyay, M., et al., The Warburg effect: insights from the past decade. Pharmacology & therapeutics, 2013. 137(3): p. 318-330. doi.org/10.1016/j. pharmthera.2012.11.003
2. Danhier, P., et al., Cancer metabolism in space and time: beyond the Warburg effect. Biochimica et Biophysica Acta (BBA)- Bioenergetics, 2017. 1858(8): p. 556-572. doi.org/10.1016/j.bbabio.2017.02.001
3. Pascale, R.M., et al., The Warburg effect 97 years after its discovery. Cancers, 2020. 12(10): p. 2819. doi.org/10.3390/ cancers12102819
4. Afonso, J., et al., Competitive glucose metabolism as a target to boost bladder cancer immunotherapy. Nature Reviews Urology, 2020. 17(2): p. 77-106.
5. Pérez-Tomás, R. and I. Pérez-Guillén, Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment. Cancers, 2020. 12(11): p. 3244. doi.org/10.3390/cancers12113244
6. Lunt, S.Y. and M.G. Vander Heiden, Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annual review of cell and developmental biology, 2011. 27(1): p. 441-464. doi.org/10.1146/ annurev-cellbio-092910-154237
7. Wu, W. and S. Zhao, Metabolic changes in cancer: beyond the Warburg effect. Acta Biochim Biophys Sin, 2013. 45(1): p. 18- 26. doi.org/10.1093/abbs/gms104
8. Demicco, M., et al., Metabolic heterogeneity in cancer. Nature Metabolism, 2024. 6(1): p. 18-38.

9. Krstic, J., T.R. Pieber, and A. Prokesch, Stratifying nutritional restriction in cancer therapy: Next stop, personalized medicine. International Review of Cell and Molecular Biology, 2020. 354: p. 231-259. doi. org/10.1016/bs.ircmb.2020.03.001
10. Fadaka, A., et al., Biology of glucose metabolization in cancer cells. Journal of Oncological Sciences, 2017. 3(2): p. 45- 51. doi.org/10.1016/j.jons.2017.06.002
11. Vazquez, A., et al., Cancer metabolism at a glance. Journal of cell science, 2016. 129(18):p.3367-3373.doi.org/10.1242/ jcs.181016
12. Lu, J., M. Tan, and Q. Cai, The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an antimetastasis mechanism.Cancer letters, 2015. 356(2):p.156-164.doi.org/10.1016/j. canlet.2014.04.001
13. Mayes, P.A. and D.A. Bender, Glycolysis and the oxidation of pyruvate. a LANGE medical book, 2003: p. 136.
14. Carbó, R. and E. Rodríguez, Relevance of Sugar Transport across the Cell Membrane. International Journal of Molecular Sciences, 2023. 24(7): p. 6085. doi. org/10.3390/ijms24076085
15. Pavlova, N.N. and C.B. Thompson, The emerging hallmarks of cancer metabolism. Cell metabolism, 2016. 23(1): p. 27-47.
16. Adekola, K.,S.T. Rosen, and M. Shanmugam, Glucose transporters in cancer metabolism. Current opinion in oncology, 2012. 24(6):p.650.DOI: 10.1097/ CCO.0b013e328356da72
17. Vander Heiden, M.G., L.C. Cantley, and C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation. science, 2009. 324(5930): p. 1029-1033. DOI: 10.1126/ science.1160809
18. de la Cruz-López, K.G., et al., Lactate in the regulation of tumor microenvironment and therapeutic approaches. Frontiers in oncology, 2019.9: p. 1143. doi.org/10.3389/ fonc.2019.01143
19. Choi, S.Y.C., et al., Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? The Journal of pathology, 2013. 230(4): p. 350-355. doi.org/10.1002/ path.4218
20. Diaz-Ruiz, R., M. Rigoulet, and A. Devin, The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochimica et Biophysica Acta (BBA)- Bioenergetics, 2011. 1807(6): p. 568-576. doi.org/10.1016/j.bbabio.2010.08.010
21. Chandel, N.S., Glycolysis. Cold Spring Harbor Perspectives in Biology, 2021. 13(5): p. a040535. doi: 10.1101/ cshperspect.a040535
22. Givan, C.V., Evolving concepts in plant glycolysis: two centuries of progress. Biological Reviews, 1999. 74(3): p. 277- 309. doi.org/10.1017/S0006323199005344
23. DeBerardinis, R.J., et al., Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proceedings of the National Academy of Sciences, 2007. 104(49): p.19345-19350.doi.org/10.1073/ pnas.0709747104
24. Wilson, D.F., Oxidative phosphorylation: regulation and role in cellular and tissue metabolism. The Journal of physiology, 2017. 595(23): p. 7023-7038. doi. org/10.1113/JP273839
25. Gupta, S., A. Roy, and B.S. Dwarakanath, Metabolic cooperation and competition in the tumor microenvironment: implications for therapy. Frontiers in oncology, 2017. 7: p. 68. doi.org/10.3389/fonc.2017.00068
26. Jiang, P., W. Du, and M. Wu, Regulation of the pentose phosphate pathway in cancer. Protein & cell, 2014. 5(8): p. 592-602. doi. org/10.1007/s13238-014-0082-8
27. Tao, Z., et al., Breast cancer: epidemiology and etiology. Cell biochemistry and biophysics, 2015. 72: p. 333-338.
28. Qadir, A.M., et al., Evaluation of Melatonin and Antioxidant Levels in the Serum of Breast Cancer Patients. BioMed Target Journal, 2024. 2(1): p. 35-42. doi. org/10.59786/bmtj.215
29. Tanoue, L.T., et al., Lung cancer screening. American journal of respiratory and critical care medicine, 2015. 191(1): p. 19-33. doi. org/10.1164/rccm.201410-1777CI
30. Tsouko, E., et al., Regulation of the pentose phosphate pathway by an androgen receptor–mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis, 2014. 3(5): p. e103-e103. doi:10.1038/oncsis.2014.18
31. Jóźwiak, P., et al., O-GlcNAcylation and metabolic reprograming in cancer. Frontiers in endocrinology, 2014. 5: p. 145. doi.org/10.3389/fendo.2014.00145
32. Kumar, M., et al., Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene, 2011. 30(7): p. 843-853.
33. Yao, S., Expression of the extended facilitative glucose transporter family (GLUT) in mouse adipose tissue. 2005, University of Liverpool.
34. Mueckler, M. and C. Makepeace, Model of the exofacial substrate-binding site and helical folding of the human Glut1 glucose transporter based on scanning mutagenesis. Biochemistry, 2009. 48(25): p. 5934-5942. doi.org/10.1021/bi900521n
35. Brown, R.S. and R.L. Wahl, Overexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study. Cancer, 1993.72(10): p.2979-2985.doi.org/10.1002/1097- 0142(19931115)72:10<2979::AIDCNCR2820721020> 3.0.CO;2-X
36. Fendt, S.-M., C. Frezza, and A. Erez, Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer discovery, 2020. 10(12): p. 1797- 1807. doi.org/10.1158/2159-8290.CD-20- 0844
37. Kreuzaler, P., et al., Adapt and conquer: Metabolic flexibility in cancer growth, invasion and evasion. Molecular metabolism, 2020. 33: p. 83-101. doi. org/10.1016/j.molmet.2019.08.021
38. Meskers, C.J., et al., Are we still on the right path (way)?: the altered expression of the pentose phosphate pathway in solid tumors and the potential of its inhibition in combination therapy. Expert Opinion on Drug Metabolism & Toxicology, 2022. 18(1): p. 61-83. doi.org/10.1080/17425255 .2022.2049234
39. DeBerardinis, R.J. and N.S. Chandel, Fundamentals of cancer metabolism. Science advances, 2016. 2(5): p. e1600200. DOI: 10.1126/sciadv.1600200
40. Jiang, M., H. Fang, and H. Tian, Metabolism of cancer cells and immune cells in the initiation, progression, and metastasis of cancer. Theranostics, 2025. 15(1): p. 155. doi: 10.7150/thno.103376